Metformin Regulates the Incretin Receptor Axis Via a Pathway Dependent on Peroxisome Proliferator-activated Receptor-α in Mice

Overview

Journal Diabetologia

Specialty Endocrinology

Date 2010 Oct 26

PMID 20972533

Citations 107

Authors

A Maida

B J Lamont

X Cao

D J Drucker

Affiliations

Soon will be listed here.

Abstract

Aims/hypothesis: Metformin is widely used for the treatment of type 2 diabetes. Although it reduces hepatic glucose production, clinical studies show that metformin may reduce plasma dipeptidyl peptidase-4 activity and increase circulating levels of glucagon-like peptide 1 (GLP-1). We examined whether metformin exerts glucoregulatory actions via modulation of the incretin axis.

Methods: Metformin action was assessed in Glp1r(-/-), Gipr(-/-), Glp1r:Gipr(-/-), Pparα (also known as Ppara)(-/-) and hyperglycaemic obese wild-type mice with or without the GLP-1 receptor (GLP1R) antagonist exendin(9-39). Experimental endpoints included glucose tolerance, plasma insulin levels, gastric emptying and food intake. Incretin receptor expression was assessed in isolated islets from metformin-treated wild-type and Pparα(-/-) mice, and in INS-1 832/3 beta cells with or without peroxisome proliferator-activated receptor (PPAR)-α or AMP-activated protein kinase (AMPK) antagonists.

Results: In wild-type mice, metformin acutely increased plasma levels of GLP-1, but not those of gastric inhibitory polypeptide or peptide YY; it also improved oral glucose tolerance and reduced gastric emptying. Metformin significantly improved oral glucose tolerance despite loss of incretin action in Glp1r(-/-), Gipr(-/-) and Glp1r(-/-) :Gipr(-/-) mice, and in wild-type mice fed a high-fat diet and treated with exendin(9-39). Levels of mRNA transcripts for Glp1r, Gipr and Pparα were significantly increased in islets from metformin-treated mice. Metformin directly increased Glp1r expression in INS-1 beta cells via a PPAR-α-dependent, AMPK-independent mechanism. Metformin failed to induce incretin receptor gene expression in islets from Pparα(-/-) mice.

Conclusions/interpretation: As metformin modulates multiple components of the incretin axis, and enhances expression of the Glp1r and related insulinotropic islet receptors through a mechanism requiring PPAR-α, metformin may be mechanistically well suited for combination with incretin-based therapies.

Citing Articles

Decrypting the Possible Mechanistic Role of Fenofibrate in Alzheimer's Disease and Type 2 Diabetes: The Truth and Mystery.

Alsaleem M, Al-Kuraishy H, Al-Gareeb A, Abdel-Fattah M, Alrouji M, Al-Harchan N J Cell Mol Med. 2025; 29(5):e70378.

PMID: 40040308 PMC: 11880132. DOI: 10.1111/jcmm.70378.

The Gut Microbiota-Related Antihyperglycemic Effect of Metformin.

Szymczak-Pajor I, Drzewoski J, Kozlowska M, Krekora J, Sliwinska A Pharmaceuticals (Basel). 2025; 18(1).

PMID: 39861118 PMC: 11768994. DOI: 10.3390/ph18010055.

Metformin Improves Glycemic Control and Postprandial Metabolism and Enhances Postprandial Glucagon-Like Peptide 1 Secretion in Patients With Type 2 Diabetes and Heart Failure: A Randomized, Double-Blind, Placebo-Controlled Trial.

Melenovsky V, Hoskova E, Velebova K, Veleba J, Borlaug B, Benes J Clin Diabetes. 2025; 43(1):23-32.

PMID: 39829685 PMC: 11739370. DOI: 10.2337/cd24-0003.

Clinical implications and pharmacological considerations of glycemic variability in patients with type 2 diabetes mellitus.

Howsawi A, Alem M Sci Rep. 2024; 14(1):24062.

PMID: 39402124 PMC: 11473953. DOI: 10.1038/s41598-024-74535-w.

Gut-Liver-Pancreas Axis Crosstalk in Health and Disease: From the Role of Microbial Metabolites to Innovative Microbiota Manipulating Strategies.

Marroncini G, Naldi L, Martinelli S, Amedei A Biomedicines. 2024; 12(7).

PMID: 39061972 PMC: 11273695. DOI: 10.3390/biomedicines12071398.

References

Kefas B, Cai Y, Kerckhofs K, Ling Z, Martens G, Heimberg H . Metformin-induced stimulation of AMP-activated protein kinase in beta-cells impairs their glucose responsiveness and can lead to apoptosis. Biochem Pharmacol. 2004; 68(3):409-16. DOI: 10.1016/j.bcp.2004.04.003. View

Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J . Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001; 108(8):1167-74. PMC: 209533. DOI: 10.1172/JCI13505. View

PEDERSON R, Satkunarajah M, McIntosh C, Scrocchi L, Flamez D, Schuit F . Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor -/- mice. Diabetes. 1998; 47(7):1046-52. DOI: 10.2337/diabetes.47.7.1046. View

Cuthbertson J, Patterson S, OHarte F, Bell P . Investigation of the effect of oral metformin on dipeptidylpeptidase-4 (DPP-4) activity in Type 2 diabetes. Diabet Med. 2009; 26(6):649-54. DOI: 10.1111/j.1464-5491.2009.02748.x. View

Yasuda N, Inoue T, Nagakura T, Yamazaki K, Kira K, Saeki T . Enhanced secretion of glucagon-like peptide 1 by biguanide compounds. Biochem Biophys Res Commun. 2002; 298(5):779-84. DOI: 10.1016/s0006-291x(02)02565-2. View

Nauck M, Niedereichholz U, Ettler R, Holst J, Orskov C, Ritzel R . Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol. 1997; 273(5):E981-8. DOI: 10.1152/ajpendo.1997.273.5.E981. View

He L, Sabet A, Djedjos S, Miller R, Sun X, Hussain M . Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell. 2009; 137(4):635-46. PMC: 2775562. DOI: 10.1016/j.cell.2009.03.016. View

Lindsay J, Duffy N, McKillop A, Ardill J, OHarte F, Flatt P . Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes. Diabet Med. 2005; 22(5):654-7. DOI: 10.1111/j.1464-5491.2005.01461.x. View

Villhauer E, Brinkman J, Naderi G, Burkey B, Dunning B, Prasad K . 1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem. 2003; 46(13):2774-89. DOI: 10.1021/jm030091l. View

10.

Hundal R, Krssak M, Dufour S, Laurent D, Lebon V, Chandramouli V . Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes. 2000; 49(12):2063-9. PMC: 2995498. DOI: 10.2337/diabetes.49.12.2063. View

11.

Dumoulin V, Moro F, Barcelo A, Dakka T, Cuber J . Peptide YY, glucagon-like peptide-1, and neurotensin responses to luminal factors in the isolated vascularly perfused rat ileum. Endocrinology. 1998; 139(9):3780-6. DOI: 10.1210/endo.139.9.6202. View

12.

Shaw R, Lamia K, Vasquez D, Koo S, Bardeesy N, DePinho R . The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science. 2005; 310(5754):1642-6. PMC: 3074427. DOI: 10.1126/science.1120781. View

13.

Green B, Irwin N, Duffy N, Gault V, Oharte F, Flatt P . Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1. Eur J Pharmacol. 2006; 547(1-3):192-9. DOI: 10.1016/j.ejphar.2006.07.043. View

14.

Maida A, Lovshin J, Baggio L, Drucker D . The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances beta-cell function but does not inhibit gastric emptying in mice. Endocrinology. 2008; 149(11):5670-8. DOI: 10.1210/en.2008-0336. View

15.

Takashima M, Ogawa W, Hayashi K, Inoue H, Kinoshita S, Okamoto Y . Role of KLF15 in regulation of hepatic gluconeogenesis and metformin action. Diabetes. 2010; 59(7):1608-15. PMC: 2889759. DOI: 10.2337/db09-1679. View

16.

Foretz M, Hebrard S, Leclerc J, Zarrinpashneh E, Soty M, Mithieux G . Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest. 2010; 120(7):2355-69. PMC: 2898585. DOI: 10.1172/JCI40671. View

17.

Hinke S, Kuhn-Wache K, Hoffmann T, Pederson R, McIntosh C, Demuth H . Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1. Biochem Biophys Res Commun. 2002; 291(5):1302-8. DOI: 10.1006/bbrc.2002.6607. View

18.

Winzell M, Ahren B . The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes. Diabetes. 2004; 53 Suppl 3:S215-9. DOI: 10.2337/diabetes.53.suppl_3.s215. View

19.

Nathan D, Buse J, Davidson M, Ferrannini E, Holman R, Sherwin R . Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2008; 52(1):17-30. DOI: 10.1007/s00125-008-1157-y. View

20.

Marchetti P, Del Guerra S, Marselli L, Lupi R, Masini M, Pollera M . Pancreatic islets from type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by metformin. J Clin Endocrinol Metab. 2004; 89(11):5535-41. DOI: 10.1210/jc.2004-0150. View